Otonomy and AGTC Present Preclinical Results for Gene Therapy Hearing Loss Program
Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced preclinical results from the company’s gene therapy collaboration with UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, […]
Foundation Park Building Sells for $12M
Avison Young real estate services announced the sale of a $12 million, newly-constructed 43,180-square-foot biotech and life science research facility at Foundation Park in Alachua. The sale, the largest in Alachua County since 2015 and part of a 1031 exchange, is the first of four buildings that are scheduled to be developed for UF Innovate […]
AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has identified Stargardt disease as the second ophthalmology program in its previously announced preclinical pipeline expansion, which also […]
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
UF startup Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced that they have entered into a strategic collaboration to co-develop and co-commercialize an […]
AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study
UF startup and UF Innovate│Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has completed enrollment of the third group in the dose-escalation portion of its Phase 1/2 clinical trial evaluating the safety […]
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019
UF startup Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced financial results for the quarter ended March 31, 2019. AGTC is a graduate of UF Innovate | Sid Martin Biotech. “Completing enrollment in the dose escalation portion of our […]
AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials
UF startup Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has achieved enrollment milestones in two of its Phase 1/2 clinical trials. The company completed enrollment of the dose escalation portion of the achromatopsia (ACHM) CNGB3 trial, […]
Gene Therapy Offers Hope to People With Achromatopsia, an Inherited Retinal Eye Disease
For years, people with inherited retinal diseases (IRDs), such as achromatopsia (ACHM), have been undiagnosed, misdiagnosed or delayed seeking genetic testing to confirm their diagnosis due to the lack of treatment options. Thanks to the rapid advancement of gene therapy research, this situation is changing. Achromatopsia patients, however, still face a long journey in pursuit […]
Gene Therapy Offers Hope to People With Achromatopsia, an Inherited Retinal Eye Disease (Fat Pitch Financials)
UF startup AGTC, a UF Innovate | Sid Martin Biotech graduate, is recruiting for two Phase I/II clinical trials for ACHM caused by mutations in the CNGB3 or the CHGA3 gene. For years, people with inherited retinal diseases (IRDs), such as achromatopsia (ACHM), have been undiagnosed, misdiagnosed or delayed seeking genetic testing to confirm their […]
AGTC Posts Quarterly Income (Healio)
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation reported a net income of $1.2 million for the first quarter of its fiscal year compared with a net loss of $1.4 million in the same quarter of 2017. General and administrative expenses decreased from $3.7 million to $3.2 million, while […]